Liposomal and sublingual forms may improve uptake modestly but still trail IV administration
The MR analysis demonstrated that GLP-1 RAs may reduce the risk of mood disorder-related ADRs, including anxiety, depression, bipolar disorder, emotionally unstable personality disorder, and suicide
Understanding the underlying mechanisms behind Ozempic-related skin reactions helps distinguish between different types of responses and their clinical significance
The FDA shortage designation for semaglutide and tirzepatide has been resolved, and the FDA has proposed excluding these drugs from the 503B bulks list
Recent studies have shown that the use of GLP-1 agonists is associated with higher rates of gastroparesis, intestinal blockages and pancreatitis
gastroparesis, bowel resections), and conditions that could interfere with breath testing accuracy (e.g., lactose intolerance, fructose intolerance) were excluded